Popescu V, Pricopie S, Totir M, Iancu R, Yasyn S, Alexandrescu C
Anatomy Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
J Med Life. 2015 Jan-Mar;8(1):8-12.
Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world. The objective of this review is to present the ophthalmic dosage and administration pathways of bevacizumab in treating refractory glaucoma patients.
VEGF = vascular endothelial growth factor, FDA = Food and Drug Administration, AMD = age-related macular degeneration.
贝伐单抗是一种针对血管内皮生长因子（VEGF）的重组人源化单克隆抗体。尽管其他VEGF抑制剂正在被批准用于治疗眼科疾病，但贝伐单抗已进入全球眼科和临床实践。本综述的目的是介绍贝伐单抗在治疗难治性青光眼患者中的眼科剂量和给药途径。
VEGF = 血管内皮生长因子，FDA = 食品药品监督管理局，AMD = 年龄相关性黄斑变性
